Abstract:Trinucleotide repeat expansions fold into long, stable hairpins and cause a variety of incurable RNA gain-of-function diseases such as Huntington's disease, the myotonic dystrophies, and spinocerebellar ataxias. One approach for treating these diseases is to bind small molecules to the structured RNAs. Both Huntington's disease-like 2 (HDL2) and myotonic dystrophy type 1 (DM1) are caused by a r(CUG) repeat expansion, or r(CUG)exp. The RNA folds into a hairpin structure with a periodic array of 1x1 nucleotide UU loops (5'CUG/3'GUC; where the underlined nucleotides indicate the Us in the internal loop) that sequester various RNA-binding proteins (RBP) and hence the source of its gain-of-function. Here, we report NMR-refined structures of single 5'CUG/3'GUC motifs in complex with three different small molecules, a di-guandinobenzoate (1), a derivative of 1 where the guanidino groups have been exchanged for imidazole (2), and a quinoline with improved drug-like properties (3). These structures were determined using nuclear magnetic resonance (NMR) spectroscopy and simulated annealing with restrained molecular dynamics (MD). Compounds 1, 2, and 3 formed stacking and hydrogen bonding interactions with the 5'CUG/3'GUC motif. Compound 3 also formed van der Waals interactions with the internal loop. The global structure of each RNA-small molecule complexes retains an A-form conformation, while the internal loops are still dynamic but to a lesser extent compared to the unbound form. These results aid our understanding of ligand-RNA interactions and enable structure-based design of small molecules with improved binding affinity for and biological activity against r(CUG)exp. As the first ever reported structures of RNA r(CUG) repeats bound to ligands, these structures can enable virtual screening campaigns combined with machine learning assisted de novo design.

Biological effects of low level exposures to ionizing radiation: Theory and practice

Precise small-molecule cleavage of an r(CUG) repeat expansion in a myotonic dystrophy mouse model

Treatment of Type 1 Myotonic Dystrophy by Engineering Site-specific RNA Endonucleases that Target (CUG)n Repeats

Software quality assurance: Testing and validation

Massively Parallel Optimization of the Linker Domain in Small Molecule Dimers Targeting a Toxic r(CUG) Repeat Expansion

NMR structures and magnetic force spectroscopy studies of small molecules binding to models of an RNA CAG repeat expansion

Small molecule targeting r(UGGAA)n disrupts RNA foci and alleviates disease phenotype in Drosophila model

Reversible cardiac disease features in an inducible CUG repeat RNA–expressing mouse model of myotonic dystrophy

The dichotomy of p53 regulation by noncoding RNAs.

rbFOX1/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1/type 2 differences

A New Compact Microstrip Integrated E-Array Patch Antenna with High Gain and High Aperture Efficiency

NMR structures of small molecules bound to a model of an RNA CUG repeat expansion

Repeat RNA expansion disorders of the nervous system: post-transcriptional mechanisms and therapeutic strategies

Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy.

Molecular Therapies for Myotonic Dystrophy Type 1: From Small Drugs to Gene Editing

Chemical characterization of substance P-like immunoreactivity in primary afferent neurones

Robust CRISPR/dCas13 RNA blockers specifically perturb miRNA-target interactions and rescue type 1 myotonic dystrophy pathology

Expression levels of core spliceosomal proteins modulate the MBNL-mediated spliceopathy in DM1

End-to-End Influence Maximization in the Field

Targeting mutant fibroblast growth factor receptors in cancer.